Nectar Lifesciences to Sell API and Formulations Business to Ceph Lifesciences

MT Newswires Live

Jul 08, 2025

Pharmaceutical company Nectar Lifesciences (NSE:NECLIFE, BOM:532649) has agreed to sell its core business division--comprising the manufacture, distribution, and marketing of active pharmaceutical ingredients (APIs) and formulations--to Ceph Lifesciences for 12.70 billion Indian rupees, according to a Tuesday filing to the Indian bourses.

The company has also agreed to sell its menthol business assets to Ceph Lifesciences for 200 million rupees.

The transactions are expected to be completed by Sept. 25.

The move is part of the company's long-term strategy to streamline its operations and strengthen its financial position.

The company plans to use the proceeds from the sale to repay existing debt, invest in new and emerging business, reward shareholders, and to fund future corporate and growth initiatives.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2549596027"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549596027\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549596027?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 12:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549596027","market":"hk","top_or_hot":-1,"title":"Nectar Lifesciences to Sell API and Formulations Business to Ceph Lifesciences","media":"MT Newswires Live","content":"<html><body><p> Pharmaceutical company Nectar Lifesciences (NSE:NECLIFE, BOM:532649) has agreed to sell its core business division--comprising the manufacture, distribution, and marketing of active pharmaceutical ingredients (APIs) and formulations--to Ceph Lifesciences for 12.70 billion Indian rupees, according to a Tuesday filing to the Indian bourses.</p><p>The company has also agreed to sell its menthol business assets to Ceph Lifesciences for 200 million rupees.</p><p>The transactions are expected to be completed by Sept. 25.</p><p>The move is part of the company's long-term strategy to streamline its operations and strengthen its financial position.</p><p>The company plans to use the proceeds from the sale to repay existing debt, invest in new and emerging business, reward shareholders, and to fund future corporate and growth initiatives.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nectar Lifesciences to Sell API and Formulations Business to Ceph Lifesciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNectar Lifesciences to Sell API and Formulations Business to Ceph Lifesciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-08 12:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Pharmaceutical company Nectar Lifesciences (NSE:NECLIFE, BOM:532649) has agreed to sell its core business division--comprising the manufacture, distribution, and marketing of active pharmaceutical ingredients (APIs) and formulations--to Ceph Lifesciences for 12.70 billion Indian rupees, according to a Tuesday filing to the Indian bourses.</p><p>The company has also agreed to sell its menthol business assets to Ceph Lifesciences for 200 million rupees.</p><p>The transactions are expected to be completed by Sept. 25.</p><p>The move is part of the company's long-term strategy to streamline its operations and strengthen its financial position.</p><p>The company plans to use the proceeds from the sale to repay existing debt, invest in new and emerging business, reward shareholders, and to fund future corporate and growth initiatives.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OTX.SI","symbol_name":"迈怡汇有限公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2549596027","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549596027","pubTimestamp":1751947395,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pharmaceutical company Nectar Lifesciences  has agreed to sell its core business division--comprising the manufacture, distribution, and marketing of active pharmaceutical ingredients  and formulations--to Ceph Lifesciences for 12.70 billion Indian rupees, according to a Tuesday filing to the Indian bourses.The company has also agreed to sell its menthol business assets to Ceph Lifesciences for 200 million rupees.The transactions are expected to be completed by Sept. 25.The move is part of the company's long-term strategy to streamline its operations and strengthen its financial position.The company plans to use the proceeds from the sale to repay existing debt, invest in new and emerging business, reward shareholders, and to fund future corporate and growth initiatives.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OTX.SI":"迈怡汇有限公司","BK6520":"工商业服务概念","BK6100":"保健护理服务"},"translate_title":"Nectar Lifesciences将API和配方业务出售给Ceph Lifesciences","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OTX.SI":1},"content_text":"Pharmaceutical company Nectar Lifesciences (NSE:NECLIFE, BOM:532649) has agreed to sell its core business division--comprising the manufacture, distribution, and marketing of active pharmaceutical ingredients (APIs) and formulations--to Ceph Lifesciences for 12.70 billion Indian rupees, according to a Tuesday filing to the Indian bourses.The company has also agreed to sell its menthol business assets to Ceph Lifesciences for 200 million rupees.The transactions are expected to be completed by Sept. 25.The move is part of the company's long-term strategy to streamline its operations and strengthen its financial position.The company plans to use the proceeds from the sale to repay existing debt, invest in new and emerging business, reward shareholders, and to fund future corporate and growth initiatives.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}